Depression Field Shifts From Resistant to Difficult-to-Treat

Psychiatric Times Pushes "Difficult-to-Treat Depression" Over "Treatment-Resistant"

Psychiatric Times published an analysis on October 9, 2026, arguing that clinicians should retire the term "treatment-resistant depression" (TRD) in favor of "difficult-to-treat depression" (DTD). This is a terminology and framework debate within psychiatry, not a regulatory change, but it directly affects how patients get evaluated before starting therapies like ketamine.

TRD has long been used in clinical practice to describe depression that persists after two or more adequate trials of antidepressants from different drug classes. According to Psychiatric Times, the problem with that label is twofold: it assumes every prior trial was actually adequate in dose, duration, and adherence, and it frames the patient as the source of failure rather than examining whether the right treatment was tried the right way in the first place.

The DTD framework instead asks clinicians to first verify that past antidepressant trials met adequacy standards before concluding a case is resistant, then stratify what is actually driving the depression, citing trauma history and inflammation among the factors named in the source article. The goal, per Psychiatric Times, is a more accurate diagnosis that points toward the treatment likeliest to help, rather than a label that implies every option has already been exhausted.

Why This Matters for Ketamine Telehealth Patients

Many people who seek ketamine therapy, whether through in-person infusion clinics or telehealth programs prescribing at-home esketamine or compounded ketamine, arrive with a TRD diagnosis already on their record. If the framework described by Psychiatric Times gains traction among prescribers, intake evaluations may start asking more pointed questions: which specific medications were tried, at what dose, for how long, and with what adherence, plus whether trauma history or markers of inflammation were ever assessed.

For telehealth ketamine providers, this is a documentation issue as much as a clinical one. A platform that only confirms "patient reports treatment-resistant depression" without verifying trial adequacy is working from a thinner evidence base than one that pulls prior prescription records or primary care notes. Readers evaluating a telehealth provider in 2026 should ask directly how intake screening verifies past treatment history, since that process shapes whether ketamine is the right next step or whether an underdosed prior trial was the real problem.

The emphasis on stratifying drivers such as trauma and inflammation also has a direct bearing on follow-up care. Depression with a strong trauma component may respond differently to ketamine than depression linked to inflammatory markers, and a provider who screens for these factors upfront is better positioned to set realistic expectations and plan integration therapy or medical follow-up alongside ketamine sessions.

What to Ask Before Starting Ketamine Treatment

Readers weighing ketamine therapy in 2026, whether through a licensed in-person clinic or a telehealth service offering at-home treatment where state law allows it, can use this shift in psychiatric framing as a prompt for better self-advocacy. Practical steps include:

• Request a copy of your prior antidepressant trial history, including doses and duration, and bring it to your ketamine intake appointment.
• Ask the provider whether they screen for trauma history and inflammatory markers as part of intake, since both are cited in the Psychiatric Times piece as relevant to treatment selection.
• Confirm how the provider defines your diagnosis: a TRD label based on two verified adequate trials carries more clinical weight than one based on a patient's own recollection that "nothing worked."
• Check your state's current rules on telehealth ketamine prescribing and required follow-up visits, since availability and monitoring requirements still vary by state as of late 2026.
• Ask about out-of-pocket costs upfront. Ketamine therapy, whether esketamine (Spravato) or off-label ketamine infusions or lozenges, is frequently not fully covered by insurance, and session counts can add up quickly if the underlying diagnosis was not well characterized first.

None of this means ketamine is the wrong choice for difficult-to-treat depression. It means the diagnostic groundwork described in the Psychiatric Times analysis is worth doing before committing to a treatment course, since it directly affects whether ketamine addresses the actual driver of a patient's depression.